The one trial a person can be in without agreeing to it

An exception with a fence around it

Informed consent is the foundation of drug research in the United States, and this site covers what a trial has to tell the person in it. There is one exception, and it is worth knowing precisely because it is so hard to use.

It covers emergency research, where the people who would be enrolled cannot consent because of the very condition being studied. A review board may approve such a study without consent from all subjects.

Nothing about it is casual. The board has to find and document every one of a list of conditions. It also needs the concurrence of a licensed physician who is a member of or consultant to the board, and who is not otherwise participating in the study.

None of this concerns peptides sold to consumers. It is here because it shows what the word research means when it is doing real work.

The situation the rule is written for

The first condition describes a specific clinical picture, and every element of it has to hold.

The subjects are "in a life-threatening situation," available treatments "are unproven or unsatisfactory," and collecting valid scientific evidence is necessary to determine whether particular interventions are safe and effective.

The rule then says something many people find surprising. That evidence "may include evidence obtained through randomized placebo-controlled investigations," so a controlled design is contemplated within the exception rather than excluded from it.

A separate condition requires that the study "could not practicably be carried out without the waiver." Inconvenience is not the test.

Why consent has to be impossible, not just difficult

The second condition is about feasibility, and it has three parts that all have to be true at once.

The subjects will not be able to consent because of their medical condition. The intervention has to be given before consent from a legally authorized representative is feasible. And there is "no reasonable way to identify prospectively the individuals likely to become eligible."

That third part is what keeps the exception narrow. If you could work out in advance who might end up in the study, you could ask them in advance, and the exception stops applying.

The rule is not satisfied by an emergency alone. It is satisfied by an emergency in which the people involved could not have been asked at any earlier point.

The prospect of benefit, and what has to exist first

A third condition requires the research to hold out the prospect of direct benefit to the subjects, and it spells out what that rests on.

The subjects face a life-threatening situation that necessitates intervention. "Appropriate animal and other preclinical studies have been conducted," and the information from them supports the potential for direct benefit to the individual subjects.

And the risks have to be reasonable against three reference points. What is known about the medical condition of the potential class of subjects. The risks and benefits of standard therapy where any exists. And what is known about the proposed intervention.

The corpus of this site repeatedly notes that laboratory and animal work does not carry to people. Here, that work is a prerequisite rather than a substitute, and it still is not enough on its own to satisfy the section.

Trying to ask anyway

The exception does not switch consent off. It builds an obligation to keep trying to obtain it.

The investigational plan has to define "the length of the potential therapeutic window based on scientific evidence." The investigator commits to attempting to contact a legally authorized representative for each subject within that window, and where feasible to asking for consent rather than proceeding without it.

Where no representative is reasonably available, there is a further step. The investigator commits, if feasible, to contacting a family member within the window and asking whether they object to the person taking part.

Both commitments produce paperwork. The investigator summarizes the efforts made and makes that summary available to the review board at continuing review.

The community has to be told twice

The additional protections in this section are unusual in American research law, because they involve people who are not in the study at all.

Before it starts, there has to be consultation with representatives of the communities where the research will be conducted and from which the subjects will be drawn.

There also has to be public disclosure to those communities, "prior to initiation of the clinical investigation, of plans for the investigation and its risks and expected benefits."

And afterwards there has to be public disclosure of enough information to apprise the community and researchers of the study, "including the demographic characteristics of the research population, and its results." An independent data monitoring committee is required as well.

What happens after a person is enrolled

The rule turns to the person themselves, and the sequence is specific.

The board must ensure procedures are in place to inform each subject at the earliest feasible opportunity of their inclusion, the details of the study, and the information in the consent document. Where the subject remains incapacitated, that goes to a legally authorized representative, or to a family member if no representative is available.

They must also be told they may stop the person's participation at any time "without penalty or loss of benefits to which the subject is otherwise entitled."

Two further situations are handled by name. Where a representative or family member was told and the subject then improves, the subject is also informed as soon as feasible. Where a subject dies before anyone could be contacted, information about the study is provided to a representative or family member if feasible.

The paperwork that makes it visible

Two provisions turn all of this into a record that exists outside the study team, and this is where the sponsor duty comes in.

A study using this exception has to run under a separate application. The rule requires it "even if an IND for the same drug product or an IDE for the same device already exists," and such applications may not be submitted as amendments to an existing one.

The sponsor must monitor the progress of all investigations using the exception. When the board sends it the required public disclosures, the sponsor promptly files copies to the application file and to a named public docket, identified by the application number.

And a refusal travels. Where a board determines it cannot approve the research, the sponsor must promptly notify the agency in writing. The same notice goes to investigators asked to take part in this or a substantially equivalent study, and to other boards asked to review one.

Why this belongs on a peptide site

The word research is used loosely in this market, and the contrast is the point.

Look at what the law requires before a single person can be studied without agreeing. A documented finding on every element, a physician's concurrence, and preclinical work already done. A defined therapeutic window, with contact attempts summarized for a board. Community consultation, and disclosure both before and after. An independent monitoring committee, a separate application, and a public docket filing.

A vial labeled for research carries none of that. Elsewhere on this site that label is explained for what it is, which is a statement about how a product may be sold rather than a description of any study.

The useful takeaway is a question to carry to any page using the word. Research is a process with records attached, and asking which records exist is usually faster than arguing about the word.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 50.24, Exception from informed consent requirements for emergency research — the documented findings at (a)(1) through (a)(7), including feasibility, prospect of direct benefit, the therapeutic window and contact commitments, community consultation and public disclosure before and after, the duty to inform subjects and representatives at (b), record retention at (c), the separate application requirement at (d), and the board's duty on a refusal at (e) — Electronic Code of Federal Regulations, Office of the Federal Register, October 1996
2. Title 21 Code of Federal Regulations section 312.54, Emergency research under section 50.24 of this chapter — the sponsor's duty to monitor all investigations using the exception, to file copies of the required public disclosures to the application file and a named public docket, and to notify the agency, investigators and other review boards where a board determines it cannot approve the research — Electronic Code of Federal Regulations, Office of the Federal Register, July 2023